Mohit Bansal
Stock Analyst at Wells Fargo
(4.14)
# 452
Out of 4,884 analysts
166
Total ratings
60.42%
Success rate
9.93%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $547.36 | +5.96% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $33.26 | +41.31% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $54.00 | +20.37% | 7 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $62 → $53 | $46.92 | +12.96% | 9 | Apr 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.77 | +30.55% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $780.67 | +40.90% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $111.75 | +25.28% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $189.28 | +26.80% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $132.87 | +5.37% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $109.45 | +55.32% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $460 | $459.62 | +0.08% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $298.24 | -6.12% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $24.55 | +22.20% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $110.00 | +54.55% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $24.00 | +191.67% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $80.93 | +35.92% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $15.01 | +79.88% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $57.50 | +56.52% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.38 | +18.20% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $129.11 | +31.67% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.54 | +85.69% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $13.66 | +13,626.21% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.73 | +0.91% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.83 | +4,219.65% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $13.88 | +36.89% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.25 | +1,900.00% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.07 | +5,507.48% | 4 | Dec 3, 2019 |
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $547.36
Upside: +5.96%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $33.26
Upside: +41.31%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $54.00
Upside: +20.37%
Bristol-Myers Squibb Company
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $46.92
Upside: +12.96%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.77
Upside: +30.55%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $780.67
Upside: +40.90%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $111.75
Upside: +25.28%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $189.28
Upside: +26.80%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $132.87
Upside: +5.37%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $109.45
Upside: +55.32%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $459.62
Upside: +0.08%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $298.24
Upside: -6.12%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $24.55
Upside: +22.20%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $110.00
Upside: +54.55%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $24.00
Upside: +191.67%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $80.93
Upside: +35.92%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $15.01
Upside: +79.88%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $57.50
Upside: +56.52%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.38
Upside: +18.20%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $129.11
Upside: +31.67%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $14.54
Upside: +85.69%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $13.66
Upside: +13,626.21%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.73
Upside: +0.91%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $0.83
Upside: +4,219.65%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $13.88
Upside: +36.89%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.25
Upside: +1,900.00%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.07
Upside: +5,507.48%